1. Home
  2. TWLO vs PODD Comparison

TWLO vs PODD Comparison

Compare TWLO & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twilio Inc.

TWLO

Twilio Inc.

HOLD

Current Price

$126.30

Market Cap

18.9B

Sector

Technology

ML Signal

HOLD

Logo Insulet Corporation

PODD

Insulet Corporation

HOLD

Current Price

$228.80

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWLO
PODD
Founded
2008
2000
Country
United States
United States
Employees
5587
N/A
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9B
17.0B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
TWLO
PODD
Price
$126.30
$228.80
Analyst Decision
Buy
Strong Buy
Analyst Count
25
20
Target Price
$143.00
$357.65
AVG Volume (30 Days)
1.8M
1.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
3.48
Revenue
N/A
$2,708,100,000.00
Revenue This Year
$14.24
$24.33
Revenue Next Year
$8.38
$19.33
P/E Ratio
$526.76
$63.05
Revenue Growth
N/A
30.73
52 Week Low
$77.51
$216.49
52 Week High
$145.90
$354.88

Technical Indicators

Market Signals
Indicator
TWLO
PODD
Relative Strength Index (RSI) 57.75 36.15
Support Level $113.82 N/A
Resistance Level $135.90 $299.75
Average True Range (ATR) 4.54 6.98
MACD 0.91 -0.84
Stochastic Oscillator 78.28 31.28

Price Performance

Historical Comparison
TWLO
PODD

About TWLO Twilio Inc.

Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Share on Social Networks: